Degarelix
CAS: 214766-78-6
Ref. 3D-PIA76678
1mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- Firmagon
- D-Alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-ly
Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist that inhibits the production of testosterone by the testes. It can be used to treat prostate cancer and other conditions caused by high levels of testosterone. Degarelix is an injectable, long-acting GnRH antagonist that is administered in three doses over a period of four months. The drug blocks the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are hormones that regulate the production of testosterone by the testes. Degarelix has been shown to improve survival rates for patients with advanced prostate cancer without causing weight gain or sexual dysfunction.